PT3494972T - Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv - Google Patents

Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv

Info

Publication number: PT3494972T
Authority: PT; Portugal
Prior art keywords: treaetment; dolutegravir; lamivudine; combinations; hiv infection
Prior art date: 2010-01-27

Application number

PT191518976T

Other languages

English (en)

Original Assignee

Viiv Healthcare Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-27

Filing date

2011-01-24

Publication date

2024-02-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3494972(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-24 Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co

2024-02-12 Publication of PT3494972T publication Critical patent/PT3494972T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PT191518976T 2010-01-27 2011-01-24 Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv PT3494972T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29858910P	2010-01-27	2010-01-27

Publications (1)

Publication Number	Publication Date
PT3494972T true PT3494972T (pt)	2024-02-12

Family

ID=44319704

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PT16187411T PT3127542T (pt)	2010-01-27	2011-01-24	Terapia antiviral
PT117374843T PT2531027E (pt)	2010-01-27	2011-01-24	Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
PT191518976T PT3494972T (pt)	2010-01-27	2011-01-24	Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
PT151649316T PT2932970T (pt)	2010-01-27	2011-01-24	Terapia antiviral

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT16187411T PT3127542T (pt)	2010-01-27	2011-01-24	Terapia antiviral
PT117374843T PT2531027E (pt)	2010-01-27	2011-01-24	Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT151649316T PT2932970T (pt)	2010-01-27	2011-01-24	Terapia antiviral

Country Status (45)

Country	Link
US (12)	US20120295898A1 (pt)
EP (6)	EP3127542B1 (pt)
JP (8)	JP2013518107A (pt)
KR (4)	KR101964923B1 (pt)
CN (2)	CN105311033B (pt)
AP (1)	AP3551A (pt)
AU (1)	AU2011209788C1 (pt)
BR (1)	BR112012018670A2 (pt)
CA (4)	CA3060290C (pt)
CL (1)	CL2012002080A1 (pt)
CO (1)	CO6602152A2 (pt)
CR (1)	CR20120423A (pt)
CY (4)	CY1116509T1 (pt)
DK (4)	DK3494972T3 (pt)
DO (2)	DOP2012000205A (pt)
EA (4)	EA037601B1 (pt)
EC (1)	ECSP12012106A (pt)
ES (4)	ES2969969T3 (pt)
FI (2)	FI3494972T3 (pt)
FR (2)	FR18C1043I2 (pt)
HK (3)	HK1209629A1 (pt)
HR (4)	HRP20240168T1 (pt)
HU (6)	HUE026849T2 (pt)
IL (5)	IL221007A (pt)
LT (4)	LT3127542T (pt)
LU (1)	LUC00090I2 (pt)
MA (1)	MA34002B1 (pt)
ME (2)	ME02182B (pt)
MX (4)	MX356891B (pt)
MY (2)	MY188334A (pt)
NO (2)	NO2932970T3 (pt)
NZ (4)	NZ627824A (pt)
PE (2)	PE20160180A1 (pt)
PH (2)	PH12016500195B1 (pt)
PL (4)	PL2932970T3 (pt)
PT (4)	PT3127542T (pt)
RS (4)	RS57728B1 (pt)
SG (3)	SG10201509476RA (pt)
SI (4)	SI2932970T1 (pt)
SM (1)	SMT201500177B (pt)
TN (1)	TN2012000376A1 (pt)
TR (1)	TR201807704T4 (pt)
UA (1)	UA105556C2 (pt)
WO (1)	WO2011094150A1 (pt)
ZA (1)	ZA201205586B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA037601B1 (ru)	2010-01-27	2021-04-20	Вайв Хелткер Компани	Комбинация для лечения вич-инфекции
NZ706223A (en)	2012-10-23	2018-11-30	Cipla Ltd	Pharmaceutical antiretroviral composition
EA037633B1 (ru)	2012-12-21	2021-04-23	Джилид Сайэнс, Инк.	Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
EP2767272A1 (en) *	2013-02-18	2014-08-20	Ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en)	2013-02-18	2015-12-23	ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
CA2916993C (en)	2013-07-12	2019-01-15	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (pt)	2013-07-12	2018-07-21
EA030695B1 (ru)	2013-09-27	2018-09-28	Мерк Шарп И Доум Корп.	Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
WO2015140569A1 (en)	2014-03-20	2015-09-24	Cipla Limited	Pharmaceutical composition
EP3151920A4 (en)	2014-06-04	2017-12-27	Sanford-Burnham Medical Research Institute	Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (pt)	2014-06-20	2018-06-23
TWI677489B (zh)	2014-06-20	2019-11-21	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016016279A1 (en)	2014-07-29	2016-02-04	Lek Pharmaceuticals D.D.	Novel hydrates of dolutegravir sodium
TWI738321B (zh)	2014-12-23	2021-09-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
BR112017020837A2 (pt)	2015-04-02	2018-07-03	Gilead Sciences, Inc.	compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
EP3334419A1 (en) *	2015-08-14	2018-06-20	Sandoz AG	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) *	2016-05-27	2017-11-30	Viiv Healthcare Company	Combinations and uses treatments thereof
WO2018028841A1 (en) *	2016-08-12	2018-02-15	Sandoz Ag	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) *	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
US20200138845A1 (en) *	2017-07-18	2020-05-07	Viiv Healthcare Company	Combination Drug Therapy
JP7384783B2 (ja)	2017-07-21	2023-11-21	ヴィーブヘルスケアカンパニー	Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
WO2019016760A1 (en) *	2017-07-21	2019-01-24	Viiv Healthcare Company	REGIMES AND PREPARATIONS FOR THE TREATMENT OF HIV INFECTIONS AND AIDS
KR20200070246A (ko) *	2017-10-13	2020-06-17	비이브 헬쓰케어 컴퍼니	이중층 제약 정제 제제
LT3938047T (lt)	2019-03-22	2022-10-10	Gilead Sciences, Inc.	Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
BR112022013452A2 (pt) *	2020-01-09	2022-09-13	Univ Washington	Combinações de agentes terapêuticos de ação prolongada e métodos das mesmas
CA3166480A1 (en)	2020-02-24	2021-09-02	Lan Jiang	Tetracyclic compounds for treating hiv infection
HRP20231654T1 (hr)	2021-01-19	2024-03-15	Gilead Sciences, Inc.	Supstituirani spojevi piridotriazina i njihove uporabe
WO2023164293A1 (en) *	2022-02-28	2023-08-31	Jericho Sciences, Llc	Methods for viral infections
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119202B1 (en)	1989-02-08	2006-10-10	Glaxo Wellcome Inc.	Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
ZA923640B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en)	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9204015D0 (en)	1992-02-25	1992-04-08	Wellcome Found	Therapeutic nucleosides
IL106507A (en)	1992-08-07	1997-11-20	Merck & Co Inc	Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en)	1992-08-07	1997-09-02	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en)	1994-02-04	1994-03-30	Wellcome Found	Chloropyrimidine intermediates
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk)	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
MY115461A (en)	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
CO4900074A1 (es) *	1996-06-25	2000-03-27	Glaxo Group Ltd	Combinaciones antivirales
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en)	1997-02-05	1999-10-12	Merck & Co., Inc.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en)	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
GB9717928D0 (en)	1997-08-22	1997-10-29	Glaxo Group Ltd	Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en)	1997-10-14	1997-12-10	Glaxo Group Ltd	Process for the synthesis of chloropurine intermediates
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US6087383A (en)	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en)	1998-03-20	1998-05-13	Glaxo Group Ltd	Process for the sythesis of hiv protease inhibitors
AU3366899A (en)	1998-03-27	1999-10-18	Regents Of The University Of California, The	Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk)	1998-04-07	2005-02-15	Брістол- Майєрс Сквібб Фарма Компані	Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
GB9815567D0 (en)	1998-07-18	1998-09-16	Glaxo Group Ltd	Antiviral compound
PL201632B1 (pl)	2000-01-31	2009-04-30	Cook Biotech	Zespół zastawki stentu
NZ529403A (en)	2001-04-10	2005-06-24	Pfizer	Pyrazole derivatives for treating HIV
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
TW200403061A (en) *	2002-06-04	2004-03-01	Glaxo Group Ltd	Pharmaceutical compositions
WO2004002433A1 (en)	2002-06-27	2004-01-08	Medivir Ab	Synergistic interaction of abacavir and alovudine
AU2004206827A1 (en) *	2003-01-14	2004-08-05	Gilead Sciences, Inc.	Compositions and methods for combination antiviral therapy
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US8691991B2 (en) *	2004-02-11	2014-04-08	Shionogi & Co., Ltd.	2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
JP4285353B2 (ja)	2004-03-05	2009-06-24	清水建設株式会社	化学物質放散度評価方法
CA2562713A1 (en) *	2004-04-14	2005-12-15	Gilead Sciences, Inc.	Phosphonate analogs of hiv integrase inhibitor compounds
EP2229945A1 (en)	2004-05-21	2010-09-22	Japan Tobacco, Inc.	Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en)	2004-05-28	2007-02-13	Bristol-Myers Squibb Company	Bicyclic heterocycles as HIV integrase inhibitors
KR20090120011A (ko)	2004-08-23	2009-11-23	테바 파마슈티컬 인더스트리즈 리미티드	고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
PL1632232T6 (pl)	2004-09-02	2022-06-27	Janssen Pharmaceutica Nv	Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
DE602005023360D1 (de)	2004-09-17	2010-10-14	Idenix Pharmaceuticals Inc	Phosphoindole als HIV-Inhibitoren
US7250421B2 (en)	2005-01-31	2007-07-31	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en)	2005-03-04	2010-02-24	Smithkline Beecham Corp	CHEMICAL COMPOUNDS
CN101212903B (zh) *	2005-04-28	2013-07-24	史密丝克莱恩比彻姆公司	具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
EP3284520B1 (en)	2005-04-28	2019-06-05	VIIV Healthcare Company	Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2008542352A (ja)	2005-06-01	2008-11-27	ビオアリアンスファルマ	キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
AU2006332664B2 (en) *	2005-12-30	2013-03-14	Gilead Sciences, Inc.	Methods for improving the pharmacokinetics of HIV integrase inhibitors
UA108605C2 (uk) *	2005-12-30	2015-05-25		Спосіб покращення фармакокінетики інгібіторів інтегрази віл
BRPI0707179A2 (pt) *	2006-01-20	2011-04-26	Tibotec Pharm Ltd	tratamento de longo termo de infecção por hiv
US20080039428A1 (en)	2006-06-29	2008-02-14	Panacos Pharmaceuticals, Inc.	Antiretroviral combination therapy
JP5599611B2 (ja)	2006-07-21	2014-10-01	ギリアードサイエンシーズ，インコーポレイテッド	抗ウイルスプロテアーゼインヒビター
MX2009003410A (es)	2006-09-29	2009-07-17	Idenix Pharmaceuticals Inc	Fosfoindoles enantiomericamente puros como inhibidores de vih.
US20080241289A1 (en)	2007-02-23	2008-10-02	Auspex Pharmaceuticals, Inc.	Preparation and utility of non-nucleoside reverse transcriptase inhibitors
SG183059A1 (en)	2007-02-23	2012-08-30	Gilead Sciences Inc	Modulators of pharmacokinetic properties of therapeutics
KR20100041798A (ko)	2007-06-29	2010-04-22	한국화학연구원	신규 ｈｉｖ 역전사효소 억제제
TW200918507A (en)	2007-06-29	2009-05-01	Gilead Sciences Inc	Novel HIV reverse transcriptase inhibitors
AR067412A1 (es)	2007-07-06	2009-10-07	Gilead Sciences Inc	Moduladores de propiedades farmaceuticas de productos terapeuticos
RU2498979C2 (ru) *	2007-07-12	2013-11-20	Тиботек Фармасьютикалз	Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2009058923A1 (en)	2007-10-31	2009-05-07	Smithkline Beecham Corporation	Ccr5 antagonists as therapeutic agents
US8466177B2 (en)	2007-11-01	2013-06-18	The Uab Research Foundation	Treating and preventing viral infections
US8108055B2 (en)	2007-12-28	2012-01-31	Larry Wong	Method, system and apparatus for controlling an electrical device
AU2008342537A1 (en) *	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel lupane derivatives
CN101977924A (zh)	2008-01-03	2011-02-16	Viro化学制药公司	新的c-21-酮基羽扇烷衍生物、其制备方法和应用
WO2009088719A1 (en)	2008-01-04	2009-07-16	Gilead Sciences, Inc.	Inhibitors of cytochrome p450
EP2257567A1 (en)	2008-02-14	2010-12-08	Virochem Pharma Inc.	Novel 17 beta lupane derivatives
WO2009148600A2 (en) *	2008-06-06	2009-12-10	Concert Pharmaceuticals, Inc.	Deuterated lysine-based compounds
PT2320908E (pt) *	2008-07-25	2014-03-06	Shionogi & Co	Pró-fármacos de dolutegravir
JP5572168B2 (ja)	2008-12-11	2014-08-13	ビーブ・ヘルスケア・カンパニー	カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
ES2641765T3 (es) *	2008-12-11	2017-11-13	Shionogi & Co., Ltd.	Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
EA037601B1 (ru)	2010-01-27	2021-04-20	Вайв Хелткер Компани	Комбинация для лечения вич-инфекции
GB201006038D0 (en)	2010-04-12	2010-05-26	Unilever Plc	Improvements relating to antiviral compositions
CN103402516B (zh)	2010-06-17	2018-01-30	富津世生物技术有限公司	用作抗病毒药物的化合物、组合物及使用方法
CA2832066C (en)	2011-04-01	2023-04-18	The Medicines Company	Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

2011
- 2011-01-24 EA EA201892277A patent/EA037601B1/ru active Protection Beyond IP Right Term
- 2011-01-24 SI SI201131492T patent/SI2932970T1/en unknown
- 2011-01-24 SI SI201130539T patent/SI2531027T1/sl unknown
- 2011-01-24 SG SG10201509476RA patent/SG10201509476RA/en unknown
- 2011-01-24 PE PE2016000261A patent/PE20160180A1/es unknown
- 2011-01-24 AU AU2011209788A patent/AU2011209788C1/en active Active
- 2011-01-24 JP JP2012551213A patent/JP2013518107A/ja active Pending
- 2011-01-24 EA EA202190473A patent/EA202190473A3/ru unknown
- 2011-01-24 DK DK19151897.6T patent/DK3494972T3/da active
- 2011-01-24 RS RS20181178A patent/RS57728B1/sr unknown
- 2011-01-24 KR KR1020187018909A patent/KR101964923B1/ko active IP Right Grant
- 2011-01-24 CA CA3060290A patent/CA3060290C/en active Active
- 2011-01-24 HR HRP20240168TT patent/HRP20240168T1/hr unknown
- 2011-01-24 DK DK15164931.6T patent/DK2932970T3/en active
- 2011-01-24 MX MX2014014689A patent/MX356891B/es unknown
- 2011-01-24 ES ES19151897T patent/ES2969969T3/es active Active
- 2011-01-24 PT PT16187411T patent/PT3127542T/pt unknown
- 2011-01-24 EP EP16187411.0A patent/EP3127542B1/en active Active
- 2011-01-24 NZ NZ627824A patent/NZ627824A/en unknown
- 2011-01-24 MY MYPI2012003346A patent/MY188334A/en unknown
- 2011-01-24 PT PT117374843T patent/PT2531027E/pt unknown
- 2011-01-24 SI SI201131593T patent/SI3127542T1/sl unknown
- 2011-01-24 CA CA2967453A patent/CA2967453C/en active Active
- 2011-01-24 MX MX2012008774A patent/MX2012008774A/es active IP Right Grant
- 2011-01-24 MA MA35145A patent/MA34002B1/fr unknown
- 2011-01-24 LT LTEP16187411.0T patent/LT3127542T/lt unknown
- 2011-01-24 SG SG2012053492A patent/SG182614A1/en unknown
- 2011-01-24 BR BR112012018670-1A patent/BR112012018670A2/pt not_active Application Discontinuation
- 2011-01-24 CN CN201510619148.8A patent/CN105311033B/zh active Active
- 2011-01-24 KR KR1020167025050A patent/KR101883750B1/ko active IP Right Grant
- 2011-01-24 CN CN201180015114.8A patent/CN102791129B/zh active Active
- 2011-01-24 HU HUE11737484A patent/HUE026849T2/en unknown
- 2011-01-24 KR KR1020127022254A patent/KR101830715B1/ko active IP Right Grant
- 2011-01-24 KR KR1020177017713A patent/KR20170078868A/ko active Application Filing
- 2011-01-24 ES ES16187411.0T patent/ES2688925T3/es active Active
- 2011-01-24 DK DK11737484.3T patent/DK2531027T3/en active
- 2011-01-24 EA EA201690872A patent/EA032868B1/ru active Protection Beyond IP Right Term
- 2011-01-24 DK DK16187411.0T patent/DK3127542T3/en active
- 2011-01-24 UA UAA201209253A patent/UA105556C2/uk unknown
- 2011-01-24 LT LTEP15164931.6T patent/LT2932970T/lt unknown
- 2011-01-24 TR TR2018/07704T patent/TR201807704T4/tr unknown
- 2011-01-24 NZ NZ601319A patent/NZ601319A/en unknown
- 2011-01-24 MX MX2014014688A patent/MX367937B/es unknown
- 2011-01-24 PT PT191518976T patent/PT3494972T/pt unknown
- 2011-01-24 ME MEP-2015-106A patent/ME02182B/me unknown
- 2011-01-24 PL PL15164931T patent/PL2932970T3/pl unknown
- 2011-01-24 ME MEP-2018-131A patent/ME03058B/me unknown
- 2011-01-24 SG SG10201707183TA patent/SG10201707183TA/en unknown
- 2011-01-24 SI SI201132101T patent/SI3494972T1/sl unknown
- 2011-01-24 RS RS20240189A patent/RS65183B1/sr unknown
- 2011-01-24 ES ES15164931.6T patent/ES2670811T3/es active Active
- 2011-01-24 EP EP18161536.0A patent/EP3351249A1/en not_active Withdrawn
- 2011-01-24 EP EP19151897.6A patent/EP3494972B1/en active Active
- 2011-01-24 CA CA2787691A patent/CA2787691C/en active Active
- 2011-01-24 PL PL11737484T patent/PL2531027T3/pl unknown
- 2011-01-24 PL PL19151897.6T patent/PL3494972T3/pl unknown
- 2011-01-24 CA CA3003988A patent/CA3003988C/en active Active
- 2011-01-24 HU HUE15164931A patent/HUE037812T2/hu unknown
- 2011-01-24 FI FIEP19151897.6T patent/FI3494972T3/fi active
- 2011-01-24 US US13/575,380 patent/US20120295898A1/en not_active Abandoned
- 2011-01-24 MY MYPI2019000564A patent/MY202778A/en unknown
- 2011-01-24 RS RS20150462A patent/RS54123B1/en unknown
- 2011-01-24 PT PT151649316T patent/PT2932970T/pt unknown
- 2011-01-24 EP EP15164931.6A patent/EP2932970B1/en not_active Revoked
- 2011-01-24 PL PL16187411T patent/PL3127542T3/pl unknown
- 2011-01-24 PE PE2012001082A patent/PE20121524A1/es active IP Right Grant
- 2011-01-24 EP EP11737484.3A patent/EP2531027B1/en not_active Revoked
- 2011-01-24 NO NO15164931A patent/NO2932970T3/no unknown
- 2011-01-24 HU HUE19151897A patent/HUE065569T2/hu unknown
- 2011-01-24 AP AP2012006445A patent/AP3551A/xx active
- 2011-01-24 ES ES11737484.3T patent/ES2543066T3/es active Active
- 2011-01-24 LT LTEP19151897.6T patent/LT3494972T/lt unknown
- 2011-01-24 EP EP23214771.0A patent/EP4316599A3/en active Pending
- 2011-01-24 MX MX2014014687A patent/MX367938B/es unknown
- 2011-01-24 NZ NZ627826A patent/NZ627826A/en unknown
- 2011-01-24 EA EA201290583A patent/EA025176B1/ru active Protection Beyond IP Right Term
- 2011-01-24 WO PCT/US2011/022219 patent/WO2011094150A1/en active Application Filing
- 2011-01-24 NZ NZ627827A patent/NZ627827A/en unknown
- 2011-01-24 RS RS20180667A patent/RS57323B1/sr unknown
- 2011-01-24 HU HUE16187411A patent/HUE040554T2/hu unknown
2012
- 2012-07-18 DO DO2012000205A patent/DOP2012000205A/es unknown
- 2012-07-18 IL IL221007A patent/IL221007A/en active IP Right Grant
- 2012-07-24 ZA ZA2012/05586A patent/ZA201205586B/en unknown
- 2012-07-24 TN TNP2012000376A patent/TN2012000376A1/en unknown
- 2012-07-26 CO CO12125933A patent/CO6602152A2/es active IP Right Grant
- 2012-07-26 CL CL2012002080A patent/CL2012002080A1/es unknown
- 2012-08-13 CR CR20120423A patent/CR20120423A/es unknown
- 2012-08-14 EC ECSP12012106 patent/ECSP12012106A/es unknown
2013
- 2013-06-06 HK HK15110408.8A patent/HK1209629A1/xx unknown
- 2013-06-06 HK HK18109751.0A patent/HK1250335A1/zh unknown
- 2013-06-06 HK HK13106716.5A patent/HK1179522A1/xx not_active IP Right Cessation
2015
- 2015-05-13 US US14/710,952 patent/US20150238496A1/en not_active Abandoned
- 2015-07-14 HR HRP20150770TT patent/HRP20150770T1/hr unknown
- 2015-07-17 CY CY20151100633T patent/CY1116509T1/el unknown
- 2015-07-24 SM SM201500177T patent/SMT201500177B/xx unknown
2016
- 2016-01-28 PH PH12016500195A patent/PH12016500195B1/en unknown
- 2016-01-29 JP JP2016015242A patent/JP2016145204A/ja active Pending
- 2016-03-18 US US15/073,728 patent/US20160199379A1/en not_active Abandoned
- 2016-04-18 IL IL245182A patent/IL245182B/en active IP Right Grant
- 2016-08-01 US US15/224,865 patent/US20160339033A1/en not_active Abandoned
- 2016-08-22 JP JP2016161610A patent/JP6268386B2/ja active Active
- 2016-12-01 US US15/366,442 patent/US10426780B2/en active Active
- 2016-12-01 US US15/366,566 patent/US20170119777A1/en not_active Abandoned
2017
- 2017-04-19 US US15/490,944 patent/US20170216284A1/en not_active Abandoned
- 2017-06-13 US US15/620,859 patent/US20170281636A1/en not_active Abandoned
- 2017-12-12 US US15/838,738 patent/US20180098992A1/en not_active Abandoned
2018
- 2018-01-31 IL IL257267A patent/IL257267B/en active IP Right Grant
- 2018-03-15 US US15/922,240 patent/US20180200254A1/en not_active Abandoned
- 2018-04-05 JP JP2018072861A patent/JP2018127473A/ja active Pending
- 2018-05-23 CY CY20181100548T patent/CY1120457T1/el unknown
- 2018-05-30 HR HRP20180855TT patent/HRP20180855T1/hr unknown
- 2018-09-26 HR HRP20181531TT patent/HRP20181531T1/hr unknown
- 2018-10-15 NO NO2018036C patent/NO2018036I1/no unknown
- 2018-10-15 FR FR18C1043C patent/FR18C1043I2/fr active Active
- 2018-10-16 CY CY2018029C patent/CY2018029I2/el unknown
- 2018-10-22 LT LTPA2018013C patent/LTC2932970I2/lt unknown
- 2018-10-23 CY CY181101087T patent/CY1121040T1/el unknown
- 2018-10-26 HU HUS1800042C patent/HUS1800042I1/hu unknown
- 2018-10-31 LU LU00090C patent/LUC00090I2/en unknown
- 2018-11-26 PH PH12018502489A patent/PH12018502489A1/en unknown
2019
- 2019-06-07 JP JP2019106635A patent/JP2019167371A/ja active Pending
- 2019-06-26 IL IL267658A patent/IL267658B/en active IP Right Grant
2020
- 2020-03-31 US US16/835,733 patent/US11234985B2/en active Active
2021
- 2021-02-26 JP JP2021030306A patent/JP2021091705A/ja active Pending
- 2021-04-01 IL IL281959A patent/IL281959B/en unknown
- 2021-07-14 DO DO2021000147A patent/DOP2021000147A/es unknown
- 2021-09-08 US US17/468,794 patent/US20210401850A1/en active Pending
2022
- 2022-03-03 JP JP2022032464A patent/JP2022071126A/ja active Pending
2023
- 2023-04-04 JP JP2023060638A patent/JP2023085431A/ja active Pending
2024
- 2024-05-31 FI FIC20240016C patent/FIC20240016I1/fi unknown
- 2024-06-03 HU HUS2400017C patent/HUS2400017I1/hu unknown
- 2024-06-06 FR FR24C1024C patent/FR24C1024I1/fr active Active

Also Published As

Publication number	Publication date
CL2012002080A1 (es)	2012-11-30
DOP2021000147A (es)	2022-01-16
CN105311033A (zh)	2016-02-10
US20120295898A1 (en)	2012-11-22
LTC2932970I2 (lt)	2022-04-25
CN102791129B (zh)	2015-09-30
US10426780B2 (en)	2019-10-01
CY1116509T1 (el)	2017-03-15
KR20180078358A (ko)	2018-07-09
DK2531027T3 (en)	2015-07-20
JP2016145204A (ja)	2016-08-12
HK1250335A1 (zh)	2018-12-14
RS57728B1 (sr)	2018-12-31
MY202778A (en)	2024-05-21
HUS2400017I1 (hu)	2024-06-28
CN102791129A (zh)	2012-11-21
JP2021091705A (ja)	2021-06-17
US20210401850A1 (en)	2021-12-30
JP6268386B2 (ja)	2018-01-31
EA201892277A1 (ru)	2019-03-29
HUE065569T2 (hu)	2024-06-28
SG10201707183TA (en)	2017-10-30
IL257267A (en)	2018-03-29
ZA201205586B (en)	2014-01-29
EA032868B1 (ru)	2019-07-31
IL245182B (en)	2018-04-30
EP2531027A1 (en)	2012-12-12
PL2932970T3 (pl)	2018-08-31
CA3060290C (en)	2022-07-12
SI3127542T1 (sl)	2018-11-30
CY2018029I1 (el)	2019-07-10
MX2012008774A (es)	2012-08-17
WO2011094150A1 (en)	2011-08-04
ES2543066T3 (es)	2015-08-14
PT2932970T (pt)	2018-06-08
PL3127542T3 (pl)	2019-03-29
CA2787691A1 (en)	2011-08-04
ES2688925T3 (es)	2018-11-07
ES2670811T3 (es)	2018-06-01
HUE040554T2 (hu)	2019-03-28
KR20160111536A (ko)	2016-09-26
NZ627826A (en)	2016-01-29
EP4316599A3 (en)	2024-04-10
CA3003988C (en)	2020-01-07
US11234985B2 (en)	2022-02-01
EP2932970B1 (en)	2018-03-21
HRP20180855T1 (hr)	2018-06-29
US20170216284A1 (en)	2017-08-03
UA105556C2 (uk)	2014-05-26
PL3494972T3 (pl)	2024-05-27
EA025176B1 (ru)	2016-11-30
HK1179522A1 (en)	2013-10-04
EA201690872A2 (ru)	2016-08-31
IL245182A0 (en)	2016-06-30
EP2932970A1 (en)	2015-10-21
EA201690872A3 (ru)	2016-12-30
DK3494972T3 (da)	2024-01-29
SI2932970T1 (en)	2018-07-31
CA2967453A1 (en)	2011-08-04
JP2023085431A (ja)	2023-06-20
KR20120128640A (ko)	2012-11-27
JP2019167371A (ja)	2019-10-03
AP2012006445A0 (en)	2012-08-31
HRP20181531T1 (hr)	2018-11-16
NZ627824A (en)	2016-02-26
JP2022071126A (ja)	2022-05-13
PL2531027T3 (pl)	2016-01-29
IL221007A0 (en)	2012-09-24
AP3551A (en)	2016-01-18
HUE026849T2 (en)	2016-08-29
MX356891B (es)	2018-06-19
HUE037812T2 (hu)	2018-09-28
DK3127542T3 (en)	2018-11-12
NZ627827A (en)	2016-02-26
JP2018127473A (ja)	2018-08-16
EA202190473A2 (ru)	2021-06-30
EA201290583A1 (ru)	2013-04-30
LT2932970T (lt)	2018-06-25
JP2017008087A (ja)	2017-01-12
HRP20150770T1 (hr)	2015-08-28
IL221007A (en)	2016-06-30
CA3060290A1 (en)	2011-08-04
CY2018029I2 (el)	2019-07-10
IL281959A (en)	2021-05-31
HUS1800042I1 (hu)	2018-11-28
US20150238496A1 (en)	2015-08-27
FR24C1024I1 (fr)	2024-07-26
IL257267B (en)	2019-08-29
RS65183B1 (sr)	2024-03-29
ME03058B (me)	2019-01-20
US20180098992A1 (en)	2018-04-12
SG10201509476RA (en)	2015-12-30
CO6602152A2 (es)	2013-01-18
US20180200254A1 (en)	2018-07-19
LT3127542T (lt)	2018-11-26
CN105311033B (zh)	2019-05-07
US20170079982A1 (en)	2017-03-23
TR201807704T4 (tr)	2018-06-21
PT2531027E (pt)	2015-09-16
NZ601319A (en)	2014-08-29
ES2969969T3 (es)	2024-05-23
MA34002B1 (fr)	2013-02-01
NO2018036I1 (no)	2018-10-15
RS57323B1 (sr)	2018-08-31
EP3494972B1 (en)	2023-12-13
PH12016500195A1 (en)	2016-12-05
LTPA2018013I1 (lt)	2018-11-12
AU2011209788B2 (en)	2014-02-06
MY188334A (en)	2021-11-30
ECSP12012106A (es)	2013-05-31
PE20160180A1 (es)	2016-05-04
CY1120457T1 (el)	2019-07-10
PE20121524A1 (es)	2012-12-03
CA2967453C (en)	2018-07-17
LUC00090I2 (pt)	2019-01-08
US20170119777A1 (en)	2017-05-04
MX367937B (es)	2019-09-12
PT3127542T (pt)	2018-11-26
EP2531027B1 (en)	2015-05-06
RS54123B1 (en)	2015-12-31
FR18C1043I2 (fr)	2019-10-11
US20160199379A1 (en)	2016-07-14
JP2013518107A (ja)	2013-05-20
CR20120423A (es)	2012-11-22
EP4316599A2 (en)	2024-02-07
SI2531027T1 (sl)	2015-08-31
KR101883750B1 (ko)	2018-07-31
SG182614A1 (en)	2012-08-30
FIC20240016I1 (fi)	2024-05-31
HRP20240168T1 (hr)	2024-04-26
SI3494972T1 (sl)	2024-03-29
KR20170078868A (ko)	2017-07-07
EP3494972A1 (en)	2019-06-12
CA3003988A1 (en)	2011-08-04
IL267658B (en)	2021-04-29
EP2531027A4 (en)	2013-07-03
ME02182B (me)	2015-10-20
SMT201500177B (it)	2015-09-07
US20160339033A1 (en)	2016-11-24
LT3494972T (lt)	2024-03-12
CY1121040T1 (el)	2019-12-11
NO2932970T3 (pt)	2018-08-18
HK1209629A1 (en)	2016-04-08
CA2787691C (en)	2018-07-17
EP3127542B1 (en)	2018-08-22
US20200230147A1 (en)	2020-07-23
FR18C1043I1 (pt)	2018-11-30
TN2012000376A1 (en)	2014-01-30
IL281959B (en)	2021-12-01
EP3127542A1 (en)	2017-02-08
PH12016500195B1 (en)	2016-12-05
KR101964923B1 (ko)	2019-04-02
DK2932970T3 (en)	2018-05-28
FI3494972T3 (fi)	2024-03-01
EA202190473A3 (ru)	2021-12-31
PH12018502489A1 (en)	2020-06-15
EP3351249A1 (en)	2018-07-25
AU2011209788C1 (en)	2014-08-28
IL267658A (en)	2019-08-29
KR101830715B1 (ko)	2018-04-04
BR112012018670A2 (pt)	2018-02-06
AU2011209788A1 (en)	2012-08-16
MX367938B (es)	2019-09-12
EA037601B1 (ru)	2021-04-20
DOP2012000205A (es)	2012-10-15
US20170281636A1 (en)	2017-10-05

Publication	Publication Date	Title
HUS2400017I1 (hu)	2024-06-28	Dolutegravir és lamivudin kombinációi HIV-fertõzés kezelésére
HRP20180218T1 (hr)	2018-06-01	Slaganje rukavica
EP2548529A4 (en)	2013-12-11	MEDICAL MANIPULATOR
PL2531409T3 (pl)	2017-08-31	Korpus puszki
EP2572688A4 (en)	2014-04-16	DISPOSABLE GARMENT
GB201100696D0 (en)	2011-03-02	Ceramic
HRP20160922T1 (hr)	2016-10-07	Oligopeptidni spojevi i njihove uporabe
ZA201106256B (en)	2012-05-30	Alkylamino compounds and uses thereof
IL222228A0 (en)	2012-12-31	Hiv vaccine
GB2485646B (en)	2017-08-30	Oleophobic laminated article
EP2608785A4 (en)	2014-05-07	LIPOMA CYCLES AND ITS USES
EP2583770A4 (en)	2016-01-20	STRUCTURAL ELEMENT
PL2491874T3 (pl)	2020-05-18	Instrument chirurgiczny o usprawnionym sposobie posługiwania się nim
ZA201302639B (en)	2013-11-27	Antibodies for the treatment of hiv
ZA201306342B (en)	2014-04-30	The treatment of viral infections
GB201020357D0 (en)	2011-01-12	Compounds and methods of making the same
IL226234A0 (en)	2013-07-31	Nucleons, ribocapsids and methods@לייצורם
GB2486213B (en)	2016-01-13	Button blank and button incorporating said blank
AU2010100755A4 (en)	2010-08-12	Haloumi Shapes
GB201012168D0 (en)	2010-09-01	Treatment of viral infections
GB201001821D0 (en)	2010-03-24	Treatment of viral infections
GB201005729D0 (en)	2010-05-19	End effectors and parts thereof
GB201005057D0 (en)	2010-05-12	HIV-1 ENV-deactivating alpha-bodies
GB201014319D0 (en)	2010-10-13	Compounds and uses thereof
PL391702A1 (pl)	2012-01-02	Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny